The human microbiome links to prostate cancer risk and treatment (Review)
- Authors:
- Bowen Xia
- Jingwei Wang
- Dongxu Zhang
- Xiaopeng Hu
-
Affiliations: Department of Urology, Beijing Chao‑Yang Hospital, Capital Medical University, Beijing 100020, P.R. China, Department of Occupational Medicine and Toxicology, Clinical Center for Interstitial Lung Diseases, Beijing Institute of Respiratory Medicine, Beijing Chaoyang Hospital, Capital Medical University, Chaoyang, Beijing 100020, P.R. China - Published online on: May 4, 2023 https://doi.org/10.3892/or.2023.8560
- Article Number: 123
-
Copyright: © Xia et al. This is an open access article distributed under the terms of Creative Commons Attribution License.
This article is mentioned in:
Abstract
 |
 |
|
Sender R, Fuchs S and Milo R: Revised estimates for the number of human and bacteria cells in the body. PLoS Biol. 14:e10025332016. View Article : Google Scholar : PubMed/NCBI | |
|
Lynch SV and Pedersen O: The human intestinal microbiome in health and disease. N Engl J Med. 375:2369–2379. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Marchesi JR, Adams DH, Fava F, Hermes GD, Hirschfield GM, Hold G, Quraishi MN, Kinross J, Smidt H, Tuohy KM, et al: The gut microbiota and host health: A new clinical frontier. Gut. 65:330–339. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Xavier JB, Young VB, Skufca J, Ginty F, Testerman T, Pearson AT, Macklin P, Mitchell A, Shmulevich I, Xie L, et al: The cancer microbiome: Distinguishing direct and indirect effects requires a systemic view. Trends Cancer. 6:192–204. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Whisner CM and Aktipis CA: The role of the microbiome in cancer initiation and progression: how microbes and cancer cells utilize excess energy and promote one another's growth. Curr Nutr Rep. 8:42–51. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Davar D, Dzutsev AK, McCulloch JA, Rodrigues RR, Chauvin JM, Morrison RM, Deblasio RN, Menna C, Ding Q, Pagliano O, et al: Fecal microbiota transplant overcomes resistance to anti-PD-1 therapy in melanoma patients. Science. 371:595–602. 2021. View Article : Google Scholar : PubMed/NCBI | |
|
Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A and Bray F: Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 71:209–249. 2021. View Article : Google Scholar : PubMed/NCBI | |
|
Litwin MS and Tan HJ: The diagnosis and treatment of prostate cancer: A review. JAMA. 317:2532–2542. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Chandrasekar T, Yang JC, Gao AC and Evans CP: Mechanisms of resistance in castration-resistant prostate cancer (CRPC). Transl Androl Urol. 4:365–380. 2015.PubMed/NCBI | |
|
Bratt O, Folkvaljon Y, Eriksson MH, Akre O, Carlsson S, Drevin L, Lissbrant IF, Makarov D, Loeb S and Stattin P: Undertreatment of men in their seventies with high-risk nonmetastatic prostate cancer. Eur Urol. 68:53–58. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Salachan PV and Sørensen KD: Dysbiotic microbes and how to find them: A review of microbiome profiling in prostate cancer. J Exp Clin Cancer Res. 41:312022. View Article : Google Scholar : PubMed/NCBI | |
|
Alexander JL, Wilson ID, Teare J, Marchesi JR, Nicholson JK and Kinross JM: Gut microbiota modulation of chemotherapy efficacy and toxicity. Nat Rev Gastroenterol Hepatol. 14:356–365. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Katongole P, Sande OJ, Joloba M, Reynolds SJ and Niyonzima N: The human microbiome and its link in prostate cancer risk and pathogenesis. Infect Agent Cancer. 15:532020. View Article : Google Scholar : PubMed/NCBI | |
|
Cohen RJ, Shannon BA, McNeal JE, Shannon T and Garrett KL: Propionibacterium acnes associated with inflammation in radical prostatectomy specimens: A possible link to cancer evolution? J Urol. 173:1969–1974. 2005. View Article : Google Scholar : PubMed/NCBI | |
|
Sfanos KS, Sauvageot J, Fedor HL, Dick JD, De Marzo AM and Isaacs WB: A molecular analysis of prokaryotic and viral DNA sequences in prostate tissue from patients with prostate cancer indicates the presence of multiple and diverse microorganisms. Prostate. 68:306–320. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Alexeyev O, Bergh J, Marklund I, Thellenberg-Karlsson C, Wiklund F, Grönberg H, Bergh A and Elgh F: Association between the presence of bacterial 16S RNA in prostate specimens taken during transurethral resection of prostate and subsequent risk of prostate cancer (Sweden). Cancer Causes Control. 17:1127–1133. 2006. View Article : Google Scholar : PubMed/NCBI | |
|
Yow MA, Tabrizi SN, Severi G, Bolton DM, Pedersen J, Giles GG and Southey MC: Australian prostate cancer bioresource: Characterisation of microbial communities within aggressive prostate cancer tissues. Infect Agent Cancer. 12:42017. View Article : Google Scholar : PubMed/NCBI | |
|
Cavarretta I, Ferrarese R, Cazzaniga W, Saita D, Lucianò R, Ceresola ER, Locatelli I, Visconti L, Lavorgna G, Briganti A, et al: The microbiome of the prostate tumor microenvironment. Eur Urol. 72:625–631. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Eisenhofer R, Minich JJ, Marotz C, Cooper A, Knight R and Weyrich LS: Contamination in low microbial biomass microbiome studies: Issues and recommendations. Trends Microbiol. 27:105–117. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Achermann Y, Goldstein EJ, Coenye T and Shirtliff ME: Propionibacterium acnes: From commensal to opportunistic biofilm-associated implant pathogen. Clin Microbiol Rev. 27:419–440. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Lloyd-Price J, Abu-Ali G and Huttenhower C: The healthy human microbiome. Genome Med. 8:512016. View Article : Google Scholar : PubMed/NCBI | |
|
Feng Y, Jaratlerdsiri W, Patrick SM, Lyons RJ, Haynes AM, Collins CC, Stricker PD, Bornman MSR and Hayes VM: Metagenomic analysis reveals a rich bacterial content in high-risk prostate tumors from African men. Prostate. 79:1731–1738. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Feng Y, Ramnarine VR, Bell R, Volik S, Davicioni E, Hayes VM, Ren S and Collins CC: Metagenomic and metatranscriptomic analysis of human prostate microbiota from patients with prostate cancer. BMC Genomics. 20:1462019. View Article : Google Scholar : PubMed/NCBI | |
|
Banerjee S, Alwine JC, Wei Z, Tian T, Shih N, Sperling C, Guzzo T, Feldman MD and Robertson ES: Microbiome signatures in prostate cancer. Carcinogenesis. 40:749–764. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Miyake M, Ohnishi K, Hori S, Nakano A, Nakano R, Yano H, Ohnishi S, Owari T, Morizawa Y, Itami Y, et al: Mycoplasma genitalium infection and chronic inflammation in human prostate cancer: Detection using prostatectomy and needle biopsy specimens. Cells. 8:2122019. View Article : Google Scholar : PubMed/NCBI | |
|
Ma J, Gnanasekar A, Lee A, Li WT, Haas M, Wang-Rodriguez J, Chang EY, Rajasekaran M and Ongkeko WM: Influence of intratumor microbiome on clinical outcome and immune processes in prostate cancer. Cancers (Basel). 12:25242020. View Article : Google Scholar : PubMed/NCBI | |
|
Salachan PV, Rasmussen M, Fredsøe J, Ulhøi B, Borre M and Sørensen KD: Microbiota of the prostate tumor environment investigated by whole-transcriptome profiling. Genome Med. 14:92022. View Article : Google Scholar : PubMed/NCBI | |
|
Stamey TA, Fair WR, Timothy MM and Chung HK: Antibacterial nature of prostatic fluid. Nature. 218:444–447. 1968. View Article : Google Scholar : PubMed/NCBI | |
|
Gatti G, Quintar AA, Andreani V, Nicola JP, Maldonado CA, Masini-Repiso AM, Rivero VE and Maccioni M: Expression of toll-like receptor 4 in the prostate gland and its association with the severity of prostate cancer. Prostate. 69:1387–1397. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Sfanos KS, Yegnasubramanian S, Nelson WG and De Marzo AM: The inflammatory microenvironment and microbiome in prostate cancer development. Nat Rev Urol. 15:11–24. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Weeber F, Ooft SN, Dijkstra KK and Voest EE: Tumor organoids as a pre-clinical cancer model for drug discovery. Cell Chem Biol. 24:1092–1100. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Guest C, Harris R, Sfanos KS, Shrestha E, Partin AW, Trock B, Mangold L, Bader R, Kozak A, Mclean S, et al: Feasibility of integrating canine olfaction with chemical and microbial profiling of urine to detect lethal prostate cancer. PLoS One. 16:e02455302021. View Article : Google Scholar : PubMed/NCBI | |
|
Hilt EE, Putonti C, Thomas-White K, Lewis AL, Visick KL, Gilbert NM and Wolfe AJ: Aerococcus urinae isolated from women with lower urinary tract symptoms: In Vitro aggregation and genome analysis. J Bacteriol. 202:e00170–e20. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Lewis DA, Brown R, Williams J, White P, Jacobson SK, Marchesi JR and Drake MJ: The human urinary microbiome; bacterial DNA in voided urine of asymptomatic adults. Front Cell Infect Microbiol. 3:412013. View Article : Google Scholar : PubMed/NCBI | |
|
Adebayo AS, Ackermann G, Bowyer RCE, Wells PM, Humphreys G, Knight R, Spector TD and Steves CJ: The urinary tract microbiome in older women exhibits host genetic and environmental influences. Cell Host Microbe. 28:298–305.e3. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Shrestha E, White JR, Yu SH, Kulac I, Ertunc O, De Marzo AM, Yegnasubramanian S, Mangold LA, Partin AW and Sfanos KS: Profiling the urinary microbiome in men with positive versus negative biopsies for prostate cancer. J Urol. 199:161–171. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Ma X, Chi C, Fan L, Dong B, Shao X, Xie S, Li M and Xue W: The microbiome of prostate fluid is associated with prostate cancer. Front Microbiol. 10:16642019. View Article : Google Scholar : PubMed/NCBI | |
|
Yu H, Meng H, Zhou F, Ni X, Shen S and Das UN: Urinary microbiota in patients with prostate cancer and benign prostatic hyperplasia. Arch Med Sci. 11:385–394. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Alanee S, El-Zawahry A, Dynda D, Dabaja A, McVary K, Karr M and Braundmeier-Fleming A: A prospective study to examine the association of the urinary and fecal microbiota with prostate cancer diagnosis after transrectal biopsy of the prostate using 16S RNA gene analysis. Prostate. 79:81–87. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Tsai KY, Wu DC, Wu WJ, Wang JW, Juan YS, Li CC, Liu CJ and Lee HY: Exploring the association between gut and urine microbiota and prostatic disease including benign prostatic hyperplasia and prostate cancer using 16S rRNA sequencing. Biomedicines. 10:26762022. View Article : Google Scholar : PubMed/NCBI | |
|
Worby CJ, Schreiber HL IV, Straub TJ, van Dijk LR, Bronson RA, Olson BS, Pinkner JS, Obernuefemann CLP, Muñoz VL, Paharik AE, et al: Longitudinal multi-omics analyses link gut microbiome dysbiosis with recurrent urinary tract infections in women. Nat Microbiol. 7:630–639. 2022. View Article : Google Scholar : PubMed/NCBI | |
|
Jeney SES, Lane F, Oliver A, Whiteson K and Dutta S: Fecal microbiota transplantation for the treatment of refractory recurrent urinary tract infection. Obstet Gynecol. 136:771–773. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
de Vos WM, Tilg H, Van Hul M and Cani PD: Gut microbiome and health: Mechanistic insights. Gut. 71:1020–1032. 2022. View Article : Google Scholar : PubMed/NCBI | |
|
Sepich-Poore GD, Zitvogel L, Straussman R, Hasty J, Wargo JA and Knight R: The microbiome and human cancer. Science. 371:eabc45522021. View Article : Google Scholar : PubMed/NCBI | |
|
Dethlefsen L, Huse S, Sogin ML and Relman DA: The pervasive effects of an antibiotic on the human gut microbiota, as revealed by deep 16S rRNA sequencing. PLoS Biol. 6:e2802008. View Article : Google Scholar : PubMed/NCBI | |
|
Boursi B, Mamtani R, Haynes K and Yang YX: Recurrent antibiotic exposure may promote cancer formation-another step in understanding the role of the human microbiota? Eur J Cancer. 51:2655–2664. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Zhong W, Wu K, Long Z, Zhou X, Zhong C, Wang S, Lai H, Guo Y, Lv D, Lu J and Mao X: Gut dysbiosis promotes prostate cancer progression and docetaxel resistance via activating NF-κB-IL6-STAT3 axis. Microbiome. 10:942022. View Article : Google Scholar : PubMed/NCBI | |
|
Amirian ES, Petrosino JF, Ajami NJ, Liu Y, Mims MP and Scheurer ME: Potential role of gastrointestinal microbiota composition in prostate cancer risk. Infect Agent Cancer. 8:422013. View Article : Google Scholar : PubMed/NCBI | |
|
Liss MA, White JR, Goros M, Gelfond J, Leach R, Johnson-Pais T, Lai Z, Rourke E, Basler J, Ankerst D and Shah DP: Metabolic biosynthesis pathways identified from fecal microbiome associated with prostate cancer. Eur Urol. 74:575–582. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Golombos DM, Ayangbesan A, O'Malley P, Lewicki P, Barlow L, Barbieri CE, Chan C, DuLong C, Abu-Ali G, Huttenhower C and Scherr DS: The role of gut microbiome in the pathogenesis of prostate cancer: A prospective, pilot study. Urology. 111:122–128. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Matsushita M, Fujita K, Motooka D, Hatano K, Fukae S, Kawamura N, Tomiyama E, Hayashi Y, Banno E, Takao T, et al: The gut microbiota associated with high-Gleason prostate cancer. Cancer Sci. 112:3125–3135. 2021. View Article : Google Scholar : PubMed/NCBI | |
|
Hayashi T, Fujita K, Nojima S, Hayashi Y, Nakano K, Ishizuya Y, Wang C, Yamamoto Y, Kinouchi T, Matsuzaki K, et al: High-fat diet-induced inflammation accelerates prostate cancer growth via IL6 signaling. Clin Cancer Res. 24:4309–4318. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Smith KS, Frugé AD, van der Pol W, Caston NE, Morrow CD, Demark-Wahnefried W and Carson TL: Gut microbial differences in breast and prostate cancer cases from two randomised controlled trials compared to matched cancer-free controls. Benef Microbes. 12:239–248. 2021. View Article : Google Scholar : PubMed/NCBI | |
|
Liu Y, Wu X and Jiang H: High dietary fat intake lowers serum equol concentration and promotes prostate carcinogenesis in a transgenic mouse prostate model. Nutr Metab (Lond). 16:242019. View Article : Google Scholar : PubMed/NCBI | |
|
Liu Y, Wu X and Jiang H: Combined maternal and post-weaning high fat diet inhibits male offspring's prostate cancer tumorigenesis in transgenic adenocarcinoma of mouse prostate model. Prostate. 79:544–553. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Moeller AH, Suzuki TA, Phifer-Rixey M and Nachman MW: Transmission modes of the mammalian gut microbiota. Science. 362:453–457. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Matsushita M, Fujita K, Hayashi T, Kayama H, Motooka D, Hase H, Jingushi K, Yamamichi G, Yumiba S, Tomiyama E, et al: Gut microbiota-derived short-chain fatty acids promote prostate cancer growth via IGF1 signaling. Cancer Res. 81:4014–4026. 2021. View Article : Google Scholar : PubMed/NCBI | |
|
Matsushita M, Fujita K, Hatano K, Hayashi T, Kayama H, Motooka D, Hase H, Yamamoto A, Uemura T, Yamamichi G, et al: High-fat diet promotes prostate cancer growth through histamine signaling. Int J Cancer. 151:623–636. 2022. View Article : Google Scholar : PubMed/NCBI | |
|
Sato H, Narita S, Ishida M, Takahashi Y, Mingguo H, Kashima S, Yamamoto R, Koizumi A, Nara T, Numakura K, et al: Specific gut microbial environment in lard diet-induced prostate cancer development and progression. Int J Mol Sci. 23:22142022. View Article : Google Scholar : PubMed/NCBI | |
|
Badgeley A, Anwar H, Modi K, Murphy P and Lakshmikuttyamma A: Effect of probiotics and gut microbiota on anti-cancer drugs: Mechanistic perspectives. Biochim Biophys Acta Rev Cancer. 1875:1884942021. View Article : Google Scholar : PubMed/NCBI | |
|
Routy B, Le Chatelier E, Derosa L, Duong CPM, Alou MT, Daillère R, Fluckiger A, Messaoudene M, Rauber C, Roberti MP, et al: Gut microbiome influences efficacy of PD-1-based immuno-therapy against epithelial tumors. Science. 359:91–97. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Matson V, Fessler J, Bao R, Chongsuwat T, Zha Y, Alegre ML, Luke JJ and Gajewski TF: The commensal microbiome is associated with anti-PD-1 efficacy in metastatic melanoma patients. Science. 359:104–108. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
González- Mercado VJ, Lim J, Berk L, Esele M, Rodríguez CS and Colón-Otero G: Gut microbiota differences in Island Hispanic Puerto Ricans and mainland non-Hispanic whites during chemoradiation for rectal cancer: A pilot study. Curr Probl Cancer. 44:1005512020. View Article : Google Scholar : PubMed/NCBI | |
|
Dai Z, Fu J, Peng X, Tang D and Song J: Intestinal microbiota: The driving force behind advances in cancer immunotherapy. Cancers (Basel). 14:47962022. View Article : Google Scholar : PubMed/NCBI | |
|
Watson PA, Arora VK and Sawyers CL: Emerging mechanisms of resistance to androgen receptor inhibitors in prostate cancer. Nat Rev Cancer. 15:701–711. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Liu Y and Jiang H: Compositional differences of gut microbiome in matched hormone-sensitive and castration-resistant prostate cancer. Transl Androl Urol. 9:1937–1944. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Li JKM, Wang LL, Wong CYP, Chiu PKF, Teoh JYC, Kwok HSW, Leung SCH, Wong SH, Tsui SKW and Ng CF: A cross-sectional study on gut microbiota in prostate cancer patients with prostatectomy or androgen deprivation therapy. Prostate Cancer Prostatic Dis. 24:1063–1072. 2021. View Article : Google Scholar : PubMed/NCBI | |
|
Kure A, Tsukimi T, Ishii C, Aw W, Obana N, Nakato G, Hirayama A, Kawano H, China T, Shimizu F, et al: Gut environment changes due to androgen deprivation therapy in patients with prostate cancer. Prostate Cancer Prostatic Dis. 13:10.1038/s41391–022-00536-3. 2022. | |
|
Pernigoni N, Zagato E, Calcinotto A, Troiani M, Mestre RP, Calì B, Attanasio G, Troisi J, Minini M, Mosole S, et al: Commensal bacteria promote endocrine resistance in prostate cancer through androgen biosynthesis. Science. 374:216–224. 2021. View Article : Google Scholar : PubMed/NCBI | |
|
Liu Y, Yang C, Zhang Z and Jiang H: Gut microbiota dysbiosis accelerates prostate cancer progression through increased LPCAT1 expression and enhanced DNA repair pathways. Front Oncol. 11:6797122021. View Article : Google Scholar : PubMed/NCBI | |
|
Huang PY, Yang YC, Wang CI, Hsiao PW, Chiang HI and Chen TW: Increase in Akkermansiaceae in gut microbiota of prostate cancer-bearing mice. Int J Mol Sci. 22:96262021. View Article : Google Scholar : PubMed/NCBI | |
|
Wilson ID and Nicholson JK: Gut microbiome interactions with drug metabolism, efficacy, and toxicity. Transl Res. 179:204–222. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Mohler JL, Gregory CW, Ford OH III, Kim D, Weaver CM, Petrusz P, Wilson EM and French FS: The androgen axis in recurrent prostate cancer. Clin Cancer Res. 10:440–448. 2004. View Article : Google Scholar : PubMed/NCBI | |
|
Buttigliero C, Tucci M, Bertaglia V, Vignani F, Bironzo P, Di Maio M and Scagliotti GV: Understanding and overcoming the mechanisms of primary and acquired resistance to abiraterone and enzalutamide in castration resistant prostate cancer. Cancer Treat Rev. 41:884–892. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Sfanos KS, Markowski MC, Peiffer LB, Ernst SE, White JR, Pienta KJ, Antonarakis ES and Ross AE: Compositional differences in gastrointestinal microbiota in prostate cancer patients treated with androgen axis-targeted therapies. Prostate Cancer Prostatic Dis. 21:539–548. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Daisley BA, Chanyi RM, Abdur-Rashid K, Al KF, Gibbons S, Chmiel JA, Wilcox H, Reid G, Anderson A, Dewar M, et al: Abiraterone acetate preferentially enriches for the gut commensal Akkermansia muciniphila in castrate-resistant prostate cancer patients. Nat Commun. 11:48222020. View Article : Google Scholar : PubMed/NCBI | |
|
Vétizou M, Pitt JM, Daillère R, Lepage P, Waldschmitt N, Flament C, Rusakiewicz S, Routy B, Roberti MP, Duong CP, et al: Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota. Science. 350:1079–1084. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Shaikh FY, White JR, Gills JJ, Hakozaki T, Richard C, Routy B, Okuma Y, Usyk M, Pandey A, Weber JS, et al: A uniform computational approach improved on existing pipelines to reveal microbiome biomarkers of nonresponse to immune checkpoint inhibitors. Clin Cancer Res. 27:2571–2583. 2021. View Article : Google Scholar : PubMed/NCBI | |
|
Terrisse S, Goubet AG, Ueda K, Thomas AM, Quiniou V, Thelemaque C, Dunsmore G, Clave E, Gamat-Huber M, Yonekura S, et al: Immune system and intestinal microbiota determine efficacy of androgen deprivation therapy against prostate cancer. J Immunother Cancer. 10:e0041912022. View Article : Google Scholar : PubMed/NCBI | |
|
Peiffer LB, White JR, Jones CB, Slottke RE, Ernst SE, Moran AE, Graff JN and Sfanos KS: Composition of gastrointestinal microbiota in association with treatment response in individuals with metastatic castrate resistant prostate cancer progressing on enzalutamide and initiating treatment with anti-PD-1 (pembrolizumab). Neoplasia. 32:1008222022. View Article : Google Scholar : PubMed/NCBI |
